Cochrane Abstracts
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation New
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation New is a topic covered in the Cochrane Abstracts.
To view the entire topic, please log in or purchase a subscription.
Evidence Central is an integrated web and mobile solution that helps clinicians quickly answer etiology, diagnosis, treatment, and prognosis questions using the latest evidence-based research. Explore these free sample topics:
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"Adjuvant Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) for the Treatment of People With Resected Stage I to III Non‐small‐cell Lung Cancer and EGFR Mutation New." Cochrane Abstracts, Evidence Central, evidence.unboundmedicine.com/evidence/view/Cochrane/431474/all/Adjuvant_epidermal_growth_factor_receptor__EGFR__tyrosine_kinase_inhibitors__TKIs__for_the_treatment_of_people_with_resected_stage_I_to_III_non‐small‐cell_lung_cancer_and_EGFR_mutation_New. Accessed 28 January 2023.
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation New. Cochrane Abstracts. https://evidence.unboundmedicine.com/evidence/view/Cochrane/431474/all/Adjuvant_epidermal_growth_factor_receptor__EGFR__tyrosine_kinase_inhibitors__TKIs__for_the_treatment_of_people_with_resected_stage_I_to_III_non‐small‐cell_lung_cancer_and_EGFR_mutation_New. Accessed January 28, 2023.
Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation New. In Cochrane Abstracts https://evidence.unboundmedicine.com/evidence/view/Cochrane/431474/all/Adjuvant_epidermal_growth_factor_receptor__EGFR__tyrosine_kinase_inhibitors__TKIs__for_the_treatment_of_people_with_resected_stage_I_to_III_non‐small‐cell_lung_cancer_and_EGFR_mutation_New
Adjuvant Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors (TKIs) for the Treatment of People With Resected Stage I to III Non‐small‐cell Lung Cancer and EGFR Mutation New [Internet]. In: Cochrane Abstracts. [cited 2023 January 28]. Available from: https://evidence.unboundmedicine.com/evidence/view/Cochrane/431474/all/Adjuvant_epidermal_growth_factor_receptor__EGFR__tyrosine_kinase_inhibitors__TKIs__for_the_treatment_of_people_with_resected_stage_I_to_III_non‐small‐cell_lung_cancer_and_EGFR_mutation_New.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - Adjuvant epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for the treatment of people with resected stage I to III non‐small‐cell lung cancer and EGFR mutation New
ID - 431474
BT - Cochrane Abstracts
UR - https://evidence.unboundmedicine.com/evidence/view/Cochrane/431474/all/Adjuvant_epidermal_growth_factor_receptor__EGFR__tyrosine_kinase_inhibitors__TKIs__for_the_treatment_of_people_with_resected_stage_I_to_III_non‐small‐cell_lung_cancer_and_EGFR_mutation_New
DB - Evidence Central
DP - Unbound Medicine
ER -
